Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, Masuyama S, Uchino S, Matsumoto H
Dept. of Surgery, Kumamoto City Hospital.
Gan To Kagaku Ryoho. 1998 Jan;25(1):59-66.
To clarify the clinical significance of PyNPase (Pyrimidine Nucleoside Phosphorylase)/ PD-ECGF activity in breast cancer, we examined the possible correlation of PyNPase activity to clinicopathological features and prognosis in 195 patients with primary breast cancer between January 1992 through December 1993. The mean PyNPase activity of primary breast cancer, assayed by ELISA method, was 140.6 U/ml, which was between that of benign breast disease (18.2) and recurrent tumors (270.9). In histological type of breast cancer, tumors with solid-tubular carcinoma had significantly higher levels of PyNPase activity. The activity of ER negative or aneuploid tumors was higher than that of ER positive or diploid tumors, respectively. And there was a significant relationship between PyNPase activity and proliferative activity determined by S-phase fraction (SPF) or DNA polymerase alpha. These findings suggested that PyNPase activity was associated with the degree of malignancy. As regards prognosis, in lower SPF (< 16%) group, patients with higher PyNPase activity had significantly lower disease--free survival rates, whereas those with higher activity had a favorable prognosis in the higher SPF (> or = 16%) group. The contradiction might be explained by the possibility that 5-FU derivatives were effective only in patients with high SPF and PyNPase activity, as all patients were treated by a regimen containing 5-FU derivatives. We suggest that PyNPase activity is associated with progression and proliferation of breast cancer, and that it may be useful for prediction of prognosis and therapeutic efficacy of 5-FU derivatives.
为阐明嘧啶核苷磷酸化酶（PyNPase）/血小板衍生内皮细胞生长因子（PD - ECGF）活性在乳腺癌中的临床意义，我们研究了1992年1月至1993年12月期间195例原发性乳腺癌患者中PyNPase活性与临床病理特征及预后的可能相关性。采用酶联免疫吸附测定（ELISA）法检测原发性乳腺癌的平均PyNPase活性为140.6 U/ml，介于良性乳腺疾病（18.2）和复发性肿瘤（270.9）之间。在乳腺癌的组织学类型中，实体 - 管状癌肿瘤的PyNPase活性水平显著更高。雌激素受体（ER）阴性或非整倍体肿瘤的活性分别高于ER阳性或二倍体肿瘤。并且PyNPase活性与通过S期分数（SPF）或DNA聚合酶α测定的增殖活性之间存在显著关系。这些发现表明PyNPase活性与恶性程度相关。关于预后，在较低SPF（<16%）组中，PyNPase活性较高的患者无病生存率显著较低，而在较高SPF（≥16%）组中，活性较高的患者预后良好。这种矛盾可能是由于所有患者均接受含5 - 氟尿嘧啶（5 - FU）衍生物的治疗方案，5 - FU衍生物可能仅对SPF和PyNPase活性高的患者有效。我们认为PyNPase活性与乳腺癌的进展和增殖相关，并且它可能有助于预测5 - FU衍生物的预后和治疗效果。
